Solid-Phase Peptide Synthesis in 2026: Where the Industry Stands
Solid-phase peptide synthesis (SPPS) remains the workhorse of peptide manufacturing, but the industry is undergoing rapid transformation driven by demand from the GLP-1 class and next-generation peptide therapeutics.
Capacity Crunch and Expansion
Global SPPS capacity has more than doubled since 2022. Bachem’s new facility in Bubendorf, Switzerland — one of the largest dedicated peptide API plants in the world — came online in late 2025. PolyPeptide Group expanded operations in Malmö, Sweden and San Diego. WuXi STA added significant capacity across its Chinese sites. Despite this, lead times for custom peptide synthesis at kilogram scale remain 12–18 months.
Technology Advances
Three areas are seeing the most innovation. First, flow chemistry is moving from academic curiosity to industrial reality — continuous-flow SPPS reduces solvent consumption by 40% and improves coupling efficiency for difficult sequences. Second, greener solvents like gamma-valerolactone (GVL) and 2-methyl-THF are replacing DMF and DCM in some processes. Third, membrane-enhanced peptide synthesis (MEPS) is showing promise for reducing purification burden.
The Purification Bottleneck
Preparative HPLC remains the rate-limiting step for most peptide APIs. A typical 30-mer therapeutic peptide requires 2–3 HPLC steps with yields of 60–70% per step. New stationary phases and simulated moving bed (SMB) chromatography are beginning to address this, but adoption is slow in the regulated GMP environment.
The Economics
Crude peptide cost at research scale ($50–200/gram) drops dramatically at commercial scale — but only if the sequence is amenable to SPPS. “Difficult sequences” with aggregation-prone regions can cost 5–10x more. This is where process development chemists earn their keep: a well-optimized coupling protocol can save millions at production scale.